Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Memirie, Solomon Tessema, Mahlet Kifle Habtemariam, Mathewos Asefa, Biniyam Tefera Deressa, Getamesay Abayneh, Biniam Tsegaye, Mihiret Woldetinsae Abraha, et al. 2018. “Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data.” Journal of Global Oncology (4) (March): 1–11. doi:10.1200/jgo.17.00175.

Published Version
doi:10.1200/JGO.17.00175

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:36640985

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Estimates of Cancer Incidence in Ethiopia in 2015 Using Population-Based Registry Data

INTRODUCTION

Cancer incidence has increased in most countries worldwide, owing to a growing and aging population and to an expansion of key risk factors, such as smoking, obesity, and unhealthy diet.\(^1,2\) Cancer has become the second leading cause of death, behind cardiovascular disease, with more than 8.7 million attributable deaths worldwide in 2015.\(^3\) Low-income countries (LICs) contribute up to 60% of this death toll.\(^4\) This is an alarming prospect, especially for LICs, where the weak health systems are severely resource constrained and already overwhelmed by the large burden of communicable diseases.

Similar to other LICs, the burden of noncommunicable diseases (NCDs) is increasing in Ethiopia. Cancer has become the second leading cause of death in the adult population.\(^5,6\) NCDs, including cancer, were among health targets of the Sustainable Development Goals\(^7\); the Global Burden of Disease Cancer Collaboration and Breast Health Global Initiative stated that cancer control strategies were to be prioritized based on local needs and that data on cancer epidemiology would be necessary for the development of national NCD and cancer action plans.\(^8,9,10,11\)

Local data on cancer epidemiology in Ethiopia are lacking. Studies from the Global Burden of Disease Cancer Collaboration and the Cancer Incidence in Five Continents Collaboration have estimated cancer incidence by cause for countries globally, and both studies used evidence from neighboring African countries to estimate cancer incidence in Ethiopia.\(^12,13,14,15\) A population-based cancer registry system has been used in Addis Ababa (Ethiopia’s capital city) since 2011, and the Global Burden of Cancer...
Study (GLOBOCAN) estimated the incidence and mortality from major types of cancer for Ethiopia using such available data for 2012. Over the years, the quality of the registry data has improved through additional staff trainings and ongoing technical support from global experts.

The fast-growing and aging population, the surge in the prevalence of risk factors such as obesity and physical inactivity, and the changes in reproductive patterns related to urbanization could increase the cancer burden in Ethiopia. Recognizing this threat, the government has recently launched a national cancer control plan. The plan set ambitious objectives to expand a range of preventive interventions, screening tests for early detection, and diagnosis and treatment, with provision of chemotherapy, surgery, radiotherapy, and palliative care. Intervention selection depends on several factors, including disease burden, cost, and effectiveness. Therefore, availability of timely local epidemiologic data is indispensable to prioritize scale-up of interventions in Ethiopia. To support this process, we have used cancer registry data to estimate the crude and age-standardized incidence rates of the commonest types of cancer in Ethiopia for the year 2015.

**METHODS**

**Study Area and Population**

Ethiopia has an estimated population of > 99 million inhabitants, and most (84%) live in rural areas. The study was undertaken in Addis Ababa, using a population-based cancer registry that is housed in Tikur Anbessa Specialized Hospital (TASH), the country’s largest tertiary hospital, as well as in university hospitals located in the six major regions of Ethiopia (home to 90% of the country population): Oromia, Amhara, the Southern Nations Nationalities and People (SNNP), Harari, Tigray, and Dire Dawa. The basis of selection was availability of cancer care services in the regional health facilities.

**Addis Ababa Cancer Registry**

Addis Ababa Cancer Registry (AACR) collects data on the population of Addis Ababa City Administration. The population is entirely urban, but with diverse ethnic and religious composition. In Addis Ababa, cancer care is provided in three public hospitals, including TASH and twelve private facilities. In most cases, a cancer diagnosis was confirmed through pathologic examination of a biopsy specimen, whereas in others it was through clinical, laboratory and imaging modalities. TASH provides the bulk of cancer care, both for Addis Ababa residents and nationally. Albeit provision of care in public hospitals and private facilities is irrespective of geographic location, the AACR unit collects data on patients with cancer only for residents of the city. In the computation of incidence, only patients with cancer from Addis Ababa were included.

The AACR unit has three full-time employees and has trained 20 contact persons in each health institution delivering cancer diagnostic/treatment services. The contact persons collect data on patients with cancer (for all ages) daily from inpatient and outpatient departments, including pathology units, using a standardized format developed by the International Agency for Research on Cancer. Cases identified in each unit are reported weekly to the AACR unit. AACR staff regularly supervises the contact persons to make sure all cases are registered and to verify data quality. When the contact persons leave the facility, AACR staff provides training to a substitute contact person. Duplicate entries are identified and corrected based on demographic data and patient phone number. On the basis of the topography (site of origin of a cancer) and tumor morphology (type of cancerous cell), each case was coded into a coding schema from the full International Classification of Diseases for Oncology, 3rd edition (ICD-O-3). Once a data set had been converted into ICD-O-3, it was checked for consistency by code verification (sex and ICD-O-3 topography and morphology) and consistency between items (age, incidence dates, sex, site, histology, age, site, site histology). The registry uses CanReg5 system for data entry, analysis, quality control, and management.

**Completeness and Data Quality**

In assessing cancer incidence, completeness of registration (the extent to which all incident cases in the population are included in the registry) is a vital factor. We assessed completeness using the following indices: stability of incidence rates over time, proportion of cases microscopically verified, and proportion of unknown basis...
of diagnosis. We could not use mortality-to-incidence ratios, because accurate data on cancer mortality were lacking.

Crude and Age-Standardized Incidence Rates

We calculated incidence of a specific cancer by 5-year age category and sex. The crude incidence rate (CIR) is the rate at which new cases occur in a population during a specific period. CIR is classically expressed as the average number of cases occurring per 100,000 population. It relates to each population as a whole and is influenced by the age structure of each population.

The age-standardized incidence rate (ASIR) is a summary of the individual age-specific rates using an external population called a standard population. This is the incidence that would be observed if the population had the age structure of the standard population and corresponds to the CIR in the standard population. Similar to CIR, ASIR is expressed as the number of new cases per 100,000 population (details are provided in the Data Supplement). We used the 1960 world population for age standardization.19 Data on the population distribution of Ethiopia and Addis Ababa were obtained from the United Nations Population Division and the Central Statistics Agency of Ethiopia.15,20 We estimated, nationally, the expected number of cases and the corresponding 95% CIs on the basis of the average incidence for each specific cancer over the 4-year period 2012 to 2015 from AACR data. Using data available for breast cancer cases only, we also assessed stage of the disease at the initial presentation.

Regional Data

To supplement the data from AACR, we collected additional hospital-based data from pathology units of five regions (Oromia, Tigray, Amhara, SNNP, Harar) and Dire Dawa for the year 2015, which allowed comparison and assessment of variations in the commonest forms of cancer across regions. We used STATA 13 and Microsoft Office Excel 2007 for further data processing and analysis.

Ethical Considerations

Ethical clearance was obtained from the scientific and ethical committee of the Ethiopian Public Health Institute and from the Office of Human Research Administration, Harvard T.H. Chan School of Public Health (Protocol # IRB16-1883).

RESULTS

AACR

Over the 2012 to 2015 period, 5,920 and 2,619 cancer cases were identified in women and men, respectively; 275 were pediatric cancer cases. Of 8,539 total cases, 89% were microscopically verified (cytology/histology examination), and 11% were verified by clinical and other laboratory investigations. None of the cases had an unknown basis of diagnosis. Comparison of incidence rates for the five commonest tumors in women and men is presented in the Data Supplement.

For 2015, we estimated 21,563 (95% CI, 17,416 to 25,660) and 42,722 (95% CI, 37,412 to 48,040) incident cancer cases in men and women, respectively, with a male-to-female ratio of approximately 1:2. The most common cancer in men age ≥ 15 years was colorectal cancer (CRC), followed by non-Hodgkin lymphoma (NHL), prostate cancer (CaP), leukemia, and lung cancer (Table 1). Disaggregation by age showed an increasing trend in incidence of CRC, NHL, and CaP with age, the highest incidence being older than age 65 years (Fig 1). In females 15 years and older, the most common cancer was breast cancer (BC), followed by cervical cancer (CC), ovarian cancer, CRC, and leukemia (Table 2). BC constituted 33% of the cancers in women and 23% of all cancers in AACR. Disaggregation by age showed increasing incidence of breast and ovarian cancers with age, with the highest incidence observed among 60- to 64-year-olds (Fig 2). For CC, a sharp increase in incidence started with 40- to 44-year-olds and peaked for 60- to 64-year-olds (Fig 2). Over 4 years, among all BC cases identified in Addis Ababa, 12% had complete staging information: most (61%) were stage III and above.

We estimated that 3,707 of all cases occurred in the pediatric age group, with leukemia being the commonest cancer (29%), followed by NHL, Wilms tumor, and retinoblastoma (Table 3).
Acute leukemia accounted for 89% (of which 91% was acute lymphocytic leukemia and 9% was acute myeloid leukemia) of all the leukemia cases in children.

Regional Data

A total of 1,648 cancer cases were identified from regional hospital-based pathology units in 2015 (Table 4): 540 cases from Amhara, 653 from Tigray, 139 from SNNP, 244 from Oromia and Harari, and 72 from Dire Dawa. All of the cases identified were microscopically verified: 543 (33%) were among men and 1,105 (67%) among women.

Regional data showed that NHL was the most common tumor in men, followed by squamous carcinoma of the skin and CRC. Fewer cases of leukemia and CaP were identified in the regions. In women, BC was the commonest malignancy, followed by CC, but with variation across the different regions. In Amhara and Tigray, CC was the leading cause.

### Table 1. ASIR and CIR per 100,000 Population and Estimated Number of Cases in 2015 for the Commonest Cancer Types Among Men in Ethiopia

| Rank | Type of Cancer               | CIR  | ASIR  | Estimated New Cases | 95% CI       |
|------|-------------------------------|------|-------|---------------------|--------------|
| 1    | Colorectal                    | 5.3  | 9.0   | 2,632               | 2,396 to 2,869 |
| 2    | Non-Hodgkin lymphoma          | 4.6  | 6.6   | 2,305               | 1,945 to 2,666 |
| 3    | Prostate                      | 4.6  | 6.4   | 2,269               | 2,104 to 2,434 |
| 4    | Leukemia                      | 2.8  | 6.3   | 1,386               | 1,138 to 1,634 |
| 5    | Lung and bronchus             | 1.9  | 3.5   | 966                 | 810 to 1,123  |
| 6    | Urinary bladder               | 1.8  | 3.4   | 905                 | 820 to 990   |
| 7    | Stomach                       | 1.8  | 3.2   | 891                 | 730 to 1,051 |
| 8    | Liver                         | 1.7  | 2.8   | 860                 | 662 to 1,058 |
| 9    | Squamous cell carcinoma of skin| 1.6  | 2.7   | 808                 | 646 to 970   |
| 10   | Connective and soft tissue    | 1.5  | 2.3   | 764                 | 486 to 1,042 |
| 11   | Esophagus                     | 1.3  | 2.3   | 642                 | 468 to 816   |
| 12   | Thyroid                       | 1.2  | 1.9   | 599                 | 488 to 711   |
| 13   | Kidney                        | 1.0  | 1.6   | 498                 | 423 to 573   |
| 14   | Nasopharynx                   | 1.0  | 1.2   | 497                 | 430 to 564   |
| 15   | Larynx                        | 0.9  | 1.1   | 456                 | 305 to 607   |
| 16   | Pancreas                      | 0.8  | 1.0   | 415                 | 341 to 490   |
| 17   | Lip and oral cavity           | 0.7  | 1.0   | 354                 | 168 to 539   |
| 18   | Bone and cartilage            | 0.6  | 1.0   | 309                 | 199 to 419   |
| 19   | Hodgkin lymphoma              | 0.6  | 1.0   | 299                 | 256 to 342   |
| 20   | Brain and nervous system      | 0.7  | 0.9   | 362                 | 196 to 528   |
| 21   | Eye                           | 0.5  | 0.9   | 266                 | 205 to 327   |
| 22   | Multiple myeloma              | 0.5  | 0.8   | 242                 | 149 to 335   |
| 23   | Tongue                        | 0.5  | 0.7   | 240                 | 202 to 278   |
| 24   | Salivary gland                | 0.4  | 0.6   | 223                 | 133 to 313   |
| 25   | Kaposi’s sarcoma              | 0.4  | 0.6   | 209                 | 156 to 262   |
| 26   | Small intestine               | 0.3  | 0.5   | 167                 | 112 to 223   |
| 27   | Tonsils                       | 0.3  | 0.5   | 148                 | 83 to 213    |
| 28   | Peritoneum and retroperitoneum| 0.3  | 0.5   | 143                 | 66 to 220    |
| 29   | Tests                         | 0.3  | 0.5   | 133                 | 64 to 203    |
| 30   | Melanoma of skin              | 0.2  | 0.4   | 124                 | 63 to 185    |
| 31   | All other types               | 2.9  | 4.9   | 1,449               | 1,174 to 1,674 |
|      | Total                         | 43.3 | 70.0  | 21,563              | 17,416 to 25,660 |

Abbreviations: ASIR, age-standardized incidence rate; CIR, crude incidence rate.
DISCUSSION

The CIR and ASIR presented are 4-year averages (2012 to 2015) from AACR, from which we estimated the national burden of cancer in Ethiopia. Given possible variation in incidence of different types of cancer over the 4 years, such average rates are likely to be better than a single-year estimate. The 10 commonly occurring cancers in Ethiopia were found to be cancers of the breast and cervix, colorectal cancer, NHL, leukemia, and cancers of the prostate, thyroid, lung, stomach, and liver. Most of these cancers have either known preventable risk factors or available screening programs for early detection and treatment that have paramount impact on clinical outcomes. Even though there are variations in ASIR, the commonest cancers identified are comparable with GLOBOCAN estimates (Data Supplement), but with notable differences. With GLOBOCAN, Kaposi sarcoma was the third (ASIR of 6.1 per 100,000) and eighth (ASIR of 3.1 per 100,000) commonest cancer in men and women, respectively. On the contrary, Kaposi sarcoma was not among the most common cancers in our estimation (ASI < 0.5 per 100,000). Kaposi sarcoma is a type of cancer that commonly occurs in patients with advanced HIV infection. Unlike neighboring countries, adult HIV prevalence in Ethiopia is low, approximately 1% (2015), with antiretroviral treatment coverage of 65% creating unfavorable conditions for a large occurrence of Kaposi sarcoma. Likewise, contrary to GLOBOCAN, we found that connective and soft tissue and bone and cartilage cancers were more common in Ethiopia.

The incidence of all cancers combined was twice as high among women than among men. The disparity is essentially due to the high rates of BC and CC among women. Although cancer incidence is higher among men in more developed nations, higher incidence was also observed in women from Eastern Africa. There is no clear understanding of what underlies the sex disparity in cancer risk. Differences could be influenced by genetic factors, sex-specific hormones, and differential exposure to risk factors. Low detection and underreporting of CaP due to absence of screening in Ethiopia could influence the observed sex disparity.

BC was the commonest cancer, constituting 23% of all cancers. Although BC incidence varies among different countries, several reports confirm that it is the most common tumor in women, and its incidence is increasing in Africa. Similar to other African countries, most cases presented at late stage with associated higher mortality levels. Wide-scale introduction of screening programs, such as clinical breast examination and ultrasound, prompt diagnosis, and high-quality treatment can greatly improve BC outcomes. Although mammography is an important screening modality for early detection of BC in high-income countries (HICs), wide-scale introduction in LICs is limited, owing to its cost and complex resource requirements. As for CC, introduction in Ethiopia of visual inspection of the cervix with acetic acid wash and immediate treatment of precancerous lesions with cryotherapy is a promising initiative. Scale-up of screening services and developing capacity to treat identified cases would have an impact on CC incidence and mortality. A comprehensive approach to CC control would include introduction of human papilloma virus vaccine into the national immunization program targeting adolescent girls.

Estimated national BC ASIR (43 per 100,000) is on par with previous estimates for Ethiopia and other Eastern African countries (ASIRs of 34 to 46 per 100,000). However, our CC estimate (22 per 100,000) is slightly lower than GLOBOCAN (26 per 100,000) and substantially different from what has been reported in Uganda (46 per 100,000), which could be partly explained by Uganda’s higher HIV prevalence. Despite our BC and CC estimates being close to those of GLOBOCAN, they could be an overestimation or underestimation. Our estimates were based on data from an urban setting, where BC risk factors (eg, contraceptive usage, lower fertility) and lifestyle factor differences (eg, obesity, early menarche, late menopause) are highly prevalent.
compared with rural settings where the majority of Ethiopians live.\textsuperscript{16,31} Although BC was most common in the capital, CC was the leading cause of cancer in two of the six regions included in the study. The observed differences identified in the regions may reflect true differences in incidence (which would have implications on national estimates) or variations in health care access and limited capacity in identifying some types of cancer that require imaging modalities. Furthermore, regional data were collected from pathology units only and could not give a comprehensive picture because they did not capture cases identified through clinical or other laboratory investigations.

CRC is the third most common cancer, with ASIR of 8 per 100,000. ASIRs of 7 and 8 per 100,000 were also reported in Zimbabwe and Uganda, respectively.\textsuperscript{8} It was more common in men than women, similar to the pattern observed globally.\textsuperscript{1,32} CRC is declining in HICs like the United States.\textsuperscript{33,34}

### Table 2. ASIR and CIR per 100,000 Population and Estimated Number of Cases in 2015 for the Commonest Cancer Types Among Women in Ethiopia

| Rank | Type of Cancer                  | CIR | ASIR | Estimated New Cases | 95% CI       |
|------|--------------------------------|-----|------|---------------------|--------------|
| 1    | Breast                         | 28.2| 43.3 | 13,987              | 13,370 to 14,605 |
| 2    | Cervix uteri                   | 12.2| 22.0 | 6,047               | 5,577 to 6,516  |
| 3    | Ovary                          | 4.9 | 8.1  | 2,436               | 2,121 to 2,750  |
| 4    | Colorectal                     | 4.3 | 7.1  | 2,137               | 1,844 to 2,430  |
| 5    | Leukemia                       | 3.8 | 5.5  | 1,886               | 1,631 to 2,140  |
| 6    | Thyroid                        | 3.3 | 4.7  | 1,653               | 1,319 to 1,987  |
| 7    | Non-Hodgkin lymphoma           | 2.8 | 4.1  | 1,374               | 1,123 to 1,625  |
| 8    | Squamous cell carcinoma of skin| 2.4 | 3.8  | 1,171               | 760 to 1,581    |
| 9    | Uterus                         | 1.9 | 3.2  | 961                 | 837 to 1,085    |
| 10   | Liver                          | 1.6 | 3.1  | 809                 | 668 to 950     |
| 11   | Esophagus                      | 1.6 | 3.0  | 783                 | 631 to 936     |
| 12   | Stomach                        | 1.5 | 2.9  | 726                 | 579 to 874     |
| 13   | Lung and bronchus              | 1.5 | 2.9  | 725                 | 671 to 778     |
| 14   | Lip and oral cavity            | 1.4 | 2.1  | 718                 | 420 to 1,016   |
| 15   | Connective and soft tissue     | 1.2 | 2.0  | 614                 | 560 to 667     |
| 16   | Kidney                         | 1.1 | 1.7  | 539                 | 397 to 681     |
| 17   | Urinary bladder                | 1.0 | 1.4  | 493                 | 401 to 584     |
| 18   | Bone and cartilage             | 1.0 | 1.3  | 485                 | 418 to 553     |
| 19   | Vula                           | 0.8 | 1.3  | 381                 | 269 to 492     |
| 20   | Brain and nervous system       | 0.8 | 1.2  | 380                 | 318 to 442     |
| 21   | Pancreas                       | 0.6 | 1.0  | 284                 | 256 to 313     |
| 22   | Nasopharynx                    | 0.6 | 0.8  | 277                 | 237 to 316     |
| 23   | Eye                            | 0.5 | 0.8  | 262                 | 214 to 310     |
| 24   | Peritoneum and retroperitoneum | 0.5 | 0.7  | 234                 | 58 to 411      |
| 25   | Gall bladder and biliary tract | 0.6 | 1.2  | 279                 | 236 to 322     |
| 26   | Salivary gland                 | 0.4 | 0.7  | 210                 | 157 to 262     |
| 27   | Vagina                         | 0.3 | 0.5  | 158                 | 77 to 238      |
| 28   | Hodgkin lymphoma               | 0.3 | 0.5  | 148                 | 99 to 197      |
| 29   | Tongue                         | 0.3 | 0.4  | 143                 | 93 to 193      |
| 30   | Anus and anal cavity           | 0.3 | 0.4  | 142                 | 85 to 200      |
| 31   | All other types                | 4.6 | 8.0  | 2,280               | 1,981 to 2,587 |
| Total|                                | 86.1| 139.3| 42,722              | 37,412 to 48,040 |

Abbreviations: ASIR, age-standardized incidence rate; CIR, crude incidence rate.
screening seems to have contributed substantially to the decline. Although a generalized screening policy may be feasible in HICs, its application in LICs such as Ethiopia should be weighed in light of severe resource constraints and competing priorities. Leukemia was most common (nearly 30% of all cancers) in children, and similar findings were reported elsewhere. Other common childhood cancers included lymphomas, Wilms tumor, retinoblastoma, bone and cartilage cancer, and rhabdomyosarcoma. Elsewhere, brain tumor is one of the commonest malignancies, but it represents only 3% of identified pediatric cancers in Ethiopia, which may relate to the complexity of diagnosing brain tumors in children where imaging studies are limited. Unlike adult cancers, most childhood malignancies are not caused by modifiable risk factors, which limits the effectiveness of public health interventions on their incidence. The prognosis of pediatric cancers in Ethiopia remains poor, but in HICs, advances in treatment have resulted in a 5-year survival rate of approximately 80%. Intensity of chemotherapy that matches disease risk and improvements in supportive care to prevent and manage treatment complications are key aspects of success. Intense chemotherapy regimens decrease cancer relapse rates but could result in treatment-related mortality, more so in LICs, where supportive care capacity is lacking. A better option in Ethiopia would be to use graduated-intensity regimens (less-intensive regimens first and intensify treatment once therapy is found safe and effective). Success in cancer care is also dependent on stable drug supplies and educational and other interventions aimed at supporting families to decrease care abandonment.

CaP is the most frequently diagnosed cancer among men in HICs (ASIR of 124 per 100,000). Estimates from sub-Saharan Africa also show that CaP is the leading cause of cancer in men, although incidence is generally lower than in HICs, with ASIRs of 18 per 100,000 (from 5 in Niger to 60 in South Africa). Our data (ASIR of 6 per 100,000) reveals a lower rate compared with the sub-Saharan African average; possible reasons include limited health care access, lack of screening, and under-reporting. Another possible reason is the population’s age structure and competing causes of mortality, because metastatic disease mainly manifests during older age. These factors are important limitations that may generally lead to underestimation of incidence of most cancers included in our analysis. Furthermore, an important challenge for population-based cancer registries in LICs is their dependence on the level of health care access that may not be universal; some patients use alternative care or die at home before seeking care, which is more prevalent in those residing in rural areas.

We have assessed here cancer incidence in Ethiopia, where cancer has become a staggering public health problem. The variation in the cancer types identified in Addis Ababa and the surrounding regions calls for expansion of cancer registry sites, including in rural areas. Improving quality and coverage of cancer registration is important to guide future cancer control programs. Prevention and control of NCDs requires a strong health system that has the capacity to develop knowledge, skills, and effective management. The Ethiopian government...
endeavor to launch health insurance could serve as an important platform for health system strengthening and improve the delivery of quality care for NCDs, including cancer.\textsuperscript{14} The inclusion of cancer treatment within national health insurance programs in the Americas has improved access to services and survival for cancers amenable to treatment, such as cervical, breast, colon, ovarian, and prostate cancer, calling for a targeted approach in the face of resource constraints.\textsuperscript{31} The fight against cancer requires both increased investment in assessing epidemiology and application of existing cancer control knowledge across all segments of the Ethiopian population.

DOI: https://doi.org/10.1200/JGO.17.00175
Published online on jgo.org on XXXX, 2018.

AUTHOR CONTRIBUTIONS

Conception and design: Solomon Tessema Memirie, Mahlet Kifle Habtemariam, Mathewos Asefa, Girma Ababi, Ahmedin Jemal, Stéphane Verguet
Administrative support: Mahlet Kifle Habtemariam
Provision of study material or patients: Solomon Tessema Memirie, Mathewos Asefa, Mihiret Woldetinsae Abraha, Girma Ababi
Collection and assembly of data: Solomon Tessema Memirie, Mathewos Asefa, Biniyam Tefera Deressa, Biniam Tsegaye, Mihiret Woldetinsae Abraha, Girma Ababi
Data analysis and interpretation: Solomon Tessema Memirie, Girma Ababi, Ahmedin Jemal, Timothy R. Rebbeck, Stéphane Verguet
Manuscript writing: All authors

Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc/rcm/cf.

Table 4. Identified Cancer Cases (distribution indicated in parentheses) From Selected Regional Health Facilities in 2015, All Ages

| Type of Cancer                | Male No. of Cases (%) | Type of Cancer                | Female No. of Cases (%) |
|-------------------------------|-----------------------|-------------------------------|-------------------------|
| Non-Hodgkin lymphoma          | 72 (13)               | Breast                        | 253 (23)                |
| Squamous cell carcinoma of skin | 71 (13)              | Cervix uteri                  | 225 (20)                |
| Colorectum                    | 50 (9)                | Thyroid                       | 94 (9)                  |
| Connective and soft tissue    | 37 (7)                | Squamous cell carcinoma of skin | 65 (6)                |
| Nasopharynx                   | 29 (5)                | Non-Hodgkin lymphoma          | 52 (5)                  |
| Thyroid                       | 29 (5)                | Ovary                         | 52 (5)                  |
| Bone and cartilage            | 27 (5)                | Colorectum                    | 44 (4)                  |
| Hodgkin lymphoma              | 27 (5)                | Connective and soft tissue    | 41 (4)                  |
| Lymph nodes                   | 23 (4)                | Stomach                       | 29 (3)                  |
| Prostate                      | 20 (4)                | Uterus                        | 27 (2)                  |
| Stomach                       | 15 (3)                | Bone and cartilage            | 24 (2)                  |
| Salivary gland                | 13 (2)                | Hodgkin lymphoma              | 23 (2)                  |
| Leukemia                      | 11 (2)                | Kidney                        | 14 (1)                  |
| Urinary bladder               | 11 (2)                | Lymph nodes                   | 14 (1)                  |
| Eye                           | 9 (2)                 | Leukemia                      | 12 (1)                  |
| Liver                         | 9 (2)                 | Vulva                         | 11 (1)                  |
| Testis                        | 9 (2)                 | Liver                         | 9 (1)                   |
| Esophagus                     | 7 (1)                 | Nasopharynx                   | 9 (1)                   |
| Kidney                        | 7 (1)                 | Salivary gland                | 9 (1)                   |
| Anus and anal cavity          | 6 (1)                 | Esophagus                     | 8 (1)                   |
| Lip and oral cavity           | 6 (1)                 | Melanoma of skin              | 7 (1)                   |
| All other sites               | 55 (10)               | All other sites               | 83 (8)                  |
| **Total**                     | **543 (100)**         | **Total**                     | **1,105 (100)**        |

[8] jgo.org JGO – Journal of Global Oncology
Affiliations
Solomon Tessema Memirie, Timothy R. Rebbeck, and Stéphane Verguet, Harvard T.H. Chan School of Public Health; Timothy R. Rebbeck, Dana-Farber Cancer Institute, Boston, MA; Mahlet Kifle Habtemariam, Federal Ministry of Health; Mathewos Asefa, Tikur Anbessa Specialized Hospital, Addis Ababa University, Addis Ababa; Biniyam Tefera Deressa, Gondar University, Gondar; Getamesay Abayneh, Haromaya University, Dire Dawa; Biniam Tsegaye, Ayder Comprehensive Specialized Hospital, Mekele University, Mekele; Mihiret Woldetinsae Abraha, Harar General Hospital, Harar; Girma Ababi, Hawassa University, Hawassa, Ethiopia; and Ahmedin Jemal, American Cancer Society, Atlanta, GA.

Support
Supported by the Takemi Program in International Health, Harvard T.H. Chan School of Public Health and the Japan Pharmaceutical Manufacturers Association. Partial funding was also received from the Department of Global Health and Population, Harvard T.H. Chan School of Public Health. The funding agents had no role in data collection, analysis, interpretation, in the writing of the manuscript or the decision to submit it for publication. We thank the Addis Ababa cancer registry staff and health care providers who were working in the health facilities included in the Addis Ababa cancer registry network and regional hospitals. They have done the major bulk of the work that made the study possible. Previous versions of this paper have been presented during seminars at Harvard University, and we received valuable comments from seminar participants.

REFERENCES
1. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, et al: Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study. JAMA Oncol 3:534-548; 2017
2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, et al: The global burden of cancer 2013. JAMA Oncol 1:505-527, 2015
3. Misganaw A, Mariam DH, Araya T: The double mortality burden among adults in Addis Ababa, Ethiopia, 2006-2009. Prev Chronic Dis 9:E84, 2012
4. Weldearegawi B, Melaku YA, Spigt M, et al: Applying the InterVA-4 model to determine causes of death in rural Ethiopia. Glob Health Action 7:25550, 2014
5. Sustainable Development Knowledge Platform: Sustainable Development Goal 3: Ensure healthy lives and promote well-being for all at all ages. https://sustainabledevelopment.un.org/sdg3
6. Love RR: Defining a global research agenda for breast cancer. Cancer 113:2366-2371, 2008 (8 suppl)
7. Anderson BO, Cazap E, El Saghir NS, et al: Optimisation of breast cancer management in low-resource and middle-resource countries: Executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol 12:387-398, 2011
8. Curado MP, Edwards B, Shin HR, et al: Cancer Incidence in Five Continents, Volume IX, no. 160. Lyon, France, International Agency for Research on Cancer, 2007
9. International Agency for Research on Cancer and World Health Organization: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx.
10. Parkin DM: NCRI Cancer Conference abstracts. A149: Four years of the African cancer registry network. http://abstracts.ncri.org.uk/abstract/four-years-of-the-african-cancer-registry-network-2
11. African Cancer Registry Network (AFCRN): Consultancies 2013. http://afcrn.org/programme-of-activities/activities-in-2013/112-consultancies-2013
12. World Health Organization: Countries: Ethiopia statistics. http://www.who.int/countries/eth/en
13. Federal Ministry of Health Ethiopia: National Cancer Control Plan 2015/2016-2019/2020. Addis Ababa, Ethiopia, Federal Ministry of Health, 2015
14. Federal Democratic Republic of Ethiopia Ministry of Health: Health Sector Transformation Plan (HSTP) (2015/2016-2019/2020). Addis Ababa, Ethiopia, Federal Ministry of Health, 2015
15. United Nations-Department of Economic and Social Affairs, Population Division: World population prospects, the 2015 revision. https://esa.un.org/unpd/wpp/Download/Standard/Population
16. Federal Democratic Republic of Ethiopia Population Census Commission: Summary and statistical report of the 2007 population and housing census. Addis Ababa, Ethiopia, Central Statistics Agency, 2008
17. African Cancer Registry Network (AFCRN): Addis Ababa city cancer registry.http://afcrn.org/membership/members/100-Addisababa
18. Parkin DM, Bray F: Evaluation of data quality in the cancer registry: Principles and methods part II. Completeness. Eur J Cancer 45:756-764, 2009
19. Segi M: Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Japan, Tohoku University School of Public Health, 1960
20. Federal Democratic Republic of Ethiopia Central Statistics Agency: Population projection of Ethiopia for all regions at wereda level from 2014-2017. Addis Ababa, Ethiopia, Central Statistics Agency, 2013
21. World Health Organization: Update Ethiopia: HIV/AIDS progress in 2014. http://www.afro.who.int/en/ethiopia/country-programmes/topics/4480-hivaids.html
22. Torre LA, Bray F, Siegel RL, et al: Global cancer statistics, 2012. CA Cancer J Clin 65:87-108, 2015
23. Cook MB, Dawsey SM, Freedman ND, et al: Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 18:1174-1182, 2009
24. Ghoncheh M, Pournamdar Z, Salehiniya H: Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17:43-46, 2016 (suppl 3)
25. World Health Organization: Breast cancer: Prevention and control. http://www.who.int/cancer/detection/breastcancer/en
26. Munzone E: Highlights from the ninth European breast cancer conference, Glasgow, 19-21 March 2014. Ecancermedicalscience 8:426-432, 2014
27. Anderson BO: Context-relevant guidelines in cancer care: Breast cancer early detection, diagnosis and treatment in low-and middle-income countries. Global Cancer Policy Making 16:36-40, 2013
28. Shiferaw N, Salvador-Davila G, Kassahun K, et al: The single-visit approach as a cervical cancer prevention strategy among women with HIV in Ethiopia: Successes and lessons learned. Glob Health Sci Pract 4:87-98, 2016
29. Ethiopian Federal Ministry of Health: Guideline for Cervical Cancer Prevention and Control in Ethiopia. Addis Ababa, Ethiopia, Federal Ministry of Health, 2015
30. World Health Organization: Comprehensive Cervical Cancer Control: A Guide to Essential
31. Central Statistical Agency (CSA) [Ethiopia] and ICF: Ethiopia Demographic and Health Survey 2016: Key Indicators Report. Addis Ababa, Ethiopia, and Rockville, MD, CSA and ICF, 2016

32. Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104-117, 2014

33. Welch HG, Robertson DJ: Colorectal cancer on the decline--Why screening can’t explain it all. N Engl J Med 374:1605-1607, 2016

34. Lambert R, Sauvaget C, Sankaranarayanan R: Mass screening for colorectal cancer is not justified in most developing countries. Int J Cancer 125:253-256, 2009

35. Ward E, DeSantis C, Robbins A, et al: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64:83-103, 2014

36. Yifru S, Muluye D: Childhood cancer in Gondar University Hospital, Northwest Ethiopia. BMC Res Notes 8:474, 2015

37. Hunger SP, Sung L, Howard SC: Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal. Pediatr Blood Cancer 52:559-565, 2009

38. Gupta S, Yeh S, Martiniuk A, et al: The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in middle-income countries: a systematic review and meta-analysis. Eur J Cancer 49:2555-2564, 2013

39. Rebbeck TR, Devesa SS, Chang B, et al: Global patterns of prostate cancer incidence, aggressiveness and mortality in men of African descent. Prostate Cancer: 10.1155/2013/560857, 2013

40. Almasi Z, Rafieimanesh H, Salehinia H: Epidemiology characteristics and trends of incidence and morphology of stomach cancer in Iran. Asian Pac J Cancer Prev 16:2757-2761, 2015

41. Sierra MS, Soerjomataram I, Antoni S, et al: Cancer patterns and trends in Central and South America. Cancer Epidemiol 44:S23-S42, 2016 (suppl 1)
AUTHOR QUERIES

AUTHOR PLEASE ANSWER ALL QUERIES

Q:1 You are responsible for detecting any errors in this proof. Confirm that all dosing information and treatment regimens are complete and accurate in text, tables, and figures, if applicable to article content.

Q:2 Please confirm that given names and surnames are identified properly by the colors indicated in the byline. Colors will not appear in print or online, and are for proofing and coding purposes only. The accuracy of given name and surname designations is important to ensure proper indexing on jco.org and PubMed.

Q:3 Please provide manufacturer name and location for STATA.

Q:4 Journal style does not allow single-sentence paragraphs; please expand this section or combine with another.

Q:5 Please approve first column heading in Tables 1 and 2.

Q:6 Figures in your article have been edited and redrawn to conform to Journal style. Please review all figure content carefully and completely for accuracy, including dosing information, axis labels, and legends, if applicable.

Q:7 Is “Addis Ababa and the surrounding regions” okay as worded here?

Q:8 Please add contributions for Getamesay Abayneh to the author contributions section.

Q:9 Please verify that all contribution information is correct for each author.

Q:10 Please verify conflicts of interest information is complete and accurate as of acceptance date.

Q:11 Please add disclosure information for Getamesay Abayneh to author disclosure section.

Q:12 URL in reference 15 does not lead to page cited; please check.

Q:13 URL for reference 21 does not work; please check.

Q:14 Cannot verify journal “Global Cancer Policy Making” (in reference 27 “Anderson, 2013”). Please check the journal name.